Artiva Biotherapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Several Venrock-affiliated entities and individuals have disclosed a combined beneficial ownership of 4.2% of Artiva Biotherapeutics, Inc.'s common stock as of June 30, 2026.
NASDAQ
5AM Ventures and associated entities have updated their beneficial ownership filing for Artiva Biotherapeutics, Inc., reporting a combined 4.8% stake as of June 30, 2026.
NASDAQ
Viking Global Investors LP and affiliated entities have reported a 5.4% beneficial ownership stake in Artiva Biotherapeutics, Inc. following a recent underwritten offering.
NASDAQ
SCHEDULE 13G/A: BlackRock Amends Schedule 13G, Disclosing 2.0% Passive Stake in Artiva Biotherapeutics
BlackRock, Inc. filed an Amendment No. 1 to its Schedule 13G, reporting a 2.0% passive beneficial ownership stake in Artiva Biotherapeutics, Inc. as of June 30, 2025.
NASDAQ
SCHEDULE 13G/A: venBio Global Strategic Fund III Reports Reduced Passive Stake in Artiva Biotherapeutics to 4.9%
venBio Global Strategic Fund III, L.P. and its affiliated entities have reported a passive beneficial ownership of 4.9% in Artiva Biotherapeutics, Inc., holding 1,198,975 shares of common stock as of March 31, 2025.
NASDAQ
BlackRock, Inc. has filed a Schedule 13G, reporting a 5.1% beneficial ownership stake in Artiva Biotherapeutics, Inc. as of March 31, 2025, held in the ordinary course of business.